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Abstract
Novel drugs are required for the elimination of infections caused by filarial worms, as most commonly used drugs largely
target the microfilariae or first stage larvae of these infections. Previous studies, conducted in vitro, have shown that
inhibition of Hsp90 kills adult Brugia pahangi. As numerous small molecule inhibitors of Hsp90 have been developed for use
in cancer chemotherapy, we tested the activity of several novel Hsp90 inhibitors in a fluorescence polarization assay and
against microfilariae and adult worms of Brugia in vitro. The results from all three assays correlated reasonably well and one
particular compound, NVP-AUY922, was shown to be particularly active, inhibiting Mf output from female worms at
concentrations as low as 5.0 nanomolar after 6 days exposure to drug. NVP-AUY922 was also active on adult worms after a
short 24 h exposure to drug. Based on these in vitro data, NVP-AUY922 was tested in vivo in a mouse model and was shown
to significantly reduce the recovery of both adult worms and microfilariae. These studies provide proof of principle that the
repurposing of currently available Hsp90 inhibitors may have potential for the development of novel agents with
macrofilaricidal properties.
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Introduction
Infections caused by the parasitic filarial nematodes Wuchereria
bancrofti, Brugia malayi and Onchocerca volvulus remain a significant
cause of pathology in the tropics. The adult stages of these
pathogens are extremely difficult to kill with currently available
drugs. Treatment relies upon two compounds, ivermectin (IVM)
or diethylcarbamazine (DEC), both of which largely target the
larval stage of the life cycle (the microfilariae, Mf). In the Global
Campaign for the Elimination of Lymphatic Filariasis, either DEC
or IVM is combined with albendazole. While this approach
effectively disrupts transmission [1], Mf repopulate the circulation,
necessitating the repeated administration of drug. As the
reproductive life span of the adult female worm is estimated to
be around 10 years for the lymphatic species [2] and longer for
Onchocerca volvulus [3], programs aimed at eradication of these
parasites are faced with a considerable challenge, as treatment
must be continued over this long timescale. At least for O. volvulus,
the repeated administration of ivermectin over many years is
associated with treatment failures [4], although whether these truly
reflect resistance remains the subject of debate. Consequently,
drugs that target adult filarial worms would be a major advantage
in control programs aimed at eliminating these parasites [5].
Heat shock protein 90 (Hsp90) has emerged in recent years as a
validated target for the therapy of various tumors [6], resulting in
the development of many Hsp90-specific small molecule inhibi-
tors. Hsp90 is essential in all eukaryotes and several recent studies
have demonstrated the activity of specific inhibitors against a
variety of tropical pathogens, such as Plasmodium [7,8], Trypanosoma
sp [9] Leishmania sp [10] and the filarial worm Brugia [11,12]. The
repurposing of compounds designed for one purpose to control of
tropical infections is an attractive proposition [13], generating
considerable enthusiasm in the pharmaceutical industry. Starting
the search for new therapeutics for these diseases with drug-like
molecules offers several short cuts, as these have already passed the
basic criteria for development, have usually been optimized for
their drug-like qualities and have often undergone toxicity testing.
Here we compare the efficacy of several classes of Hsp90
inhibitor against the lymphatic filarial nematode Brugia. The
prototype Hsp90 inhibitor is geldanamycin (GA), a fermentation
product of Streptomyces species that binds at the N-terminal ATP
domain of Hsp90 disrupting its function [14]. Hsp90 acts as a
molecular chaperone helping to fold and stabilize a variety of
different proteins, the so-called ‘client’ proteins, many of which are
involved in signal transduction [6]. The realization that Hsp90
client proteins, such as those encoded by oncogenes, were unable
to attain their active conformation and were degraded following
exposure to GA led to studies in animal models of various cancers.
However, GA suffers from several target-unrelated limitations as
an in vivo chemotherapeutic agent because of its chemical
structure, as it contains a benzoquinone ring, rendering it
hepatotoxic [15]. GA has been extensively modified to limit these
liabilities and some of the resulting derivatives are still undergoing
clinical assessment (reviewed in [16]). However, most recent efforts
have been directed at developing synthetic small molecule
inhibitors of distinct chemical scaffold, such as the purine-scaffold
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series [17], that bind at the same site as GA but lack the target-
unrelated liabilities. These molecules have undergone considerable
modification and one compound, PU-H71, shows potential in the
clinic [18,19]. Several additional N-terminal Hsp90 inhibitors
have been identified in high throughput screens, including the
pyrazole, isoxazole and triazole resorcinol classes such as VER-
50589, NVP-AUY922 and STA-9090 (ganetespib), respectively
[20,21]. NVP-AUY922 is progressing through Phase I/II clinical
trials while STA-9090 has advanced to Phase III [22,23]. An
additional class of compound, the Serenex series, also progressed
to phase I/II clinical trials (reviewed in [22]). In this paper we
report the efficacy of five inhibitors, representing four different
classes of compound, on adult Brugia in vitro and compare the
results with those from screens based on Mf viability and a
fluorescence polarization assay. We focus on the most active
compound, NVP-AUY922, and describe its in vitro effects on three
life cycle stages of Brugia and its efficacy against adult worms in vivo.
Methods
Ethics statement
All animal protocols were carried out in accordance with the
guidelines of the UK Home Office, under the Animal (Scientific
Procedures) Act 1986, following approval by the University of
Glasgow Ethical Review Panel. Experiments were performed
under the authority of the UK Home Office, project numbers 60/
4448 and 60/3792.
Parasites
The Brugia pahangi life cycle was maintained by serial passage
through mosquitoes (Aedes aegypti, Refm) and jirds, Meriones
unguiculatus, as described previously [24].
Preparation of worm extracts
Adult worms of B. pahangi were obtained from infected jirds after
3–4 months, exactly as described previously [11] and were frozen
in liquid nitrogen, ground in a pestle and mortar to a fine powder
and re-suspended in an appropriate volume of HFB assay buffer
(20 mM HEPES, pH 7.3, 50 mM KCl, 5 mM MgCl2, 20 mM
Na2MoO4, 1% NP40). Protein concentrations were estimated
using the BioRad protein assay. At this point lysates were freeze-
dried for shipping to the USA.
Fluorescence polarization assay
The FP assay was set up essentially as described previously
[12,25]. In brief, assays were performed in black 96-well half-
volume non-binding microtiter plates (Corning #3686) in a total
volume of 50 ml per well. Assay buffer (HFB2) contained 20 mM
HEPES, pH 7.3, 50 mM KCl, 2 mM EDTA, 0.01% Triton-
X100, 0.1 mg/ml bovine gamma globulin (Sigma #G5009, Saint
Louis, MO), 2 mM DTT (Sigma, Saint Louis, MO) and protease
inhibitor cocktail (Roche #11836170, Indianapolis, IN). The
equilibrium binding of Cy3B-GA and recombinant human
Hsp90a (Enzo Life Sciences, Farmingdale, NY USA) or parasite
lysate was determined by creating a two-fold dilution series of
protein/extract for an eleven-point curve with the first column
containing no protein. The dilution series was incubated with
6 nM Cy3B-GA in triplicate at 4uC with gentle shaking for
different periods of time and FP measurements taken on a Safire2
plate reader (Tecan, San Jose, CA) with excitation and emission
wavelengths of 530 nm and 585 nm, respectively, and a band-
width of 20 nm. All FP values are expressed in millipolarization
(mP) units with the mP value of free Cy3B-GA probe set to 50.
Equilibrium binding constants were determined by nonlinear
regression using a one-site binding model (GraphPad Prism
software).
Competition FP assays
The relative binding affinities of inhibitors to human or
parasite-derived Hsp90 was determined using competitive FP
binding assays. Human Hsp90 was used at a concentration
resulting in 50% maximal binding of 6 nM Cy3B-GA (2.4 nM for
human Hsp90a). For parasite-derived Hsp90, an amount of
parasite lysate resulting in 50% of maximal Cy3B-GA binding was
used. The drugs tested in the FP assay were GA and 17-AAG,
CCTC018159, VER-49009, VER-50589, NBP-AUY922, NVP-
BEP800, CAY 10607, BIIB021, PU-H71, SNX-2112, SNX-9203
and HSP990. Stock solutions of each compound were prepared in
DMSO at a concentration of 10 mM and 3-fold serial dilutions
prepared in DMSO for eleven point curves. Drugs were then
diluted 100-fold into HFB2 assay buffer containing 12 nM Cy3B-
GA in 96-well storage plates to create 2X drug solutions. Drug
solutions (25 ml/well) were then transferred in duplicate to 96-well
black assay plates (Corning#3686) containing 25 ml HFB2 with
2X the final desired concentration of Hsp90. The final concen-
tration of Cy3B-GA was 6 nM and the final DMSO concentration
in all wells was 0.5%. Free Cy3B-GA (mP set to 50) and buffer
only (background) wells were included as controls on each plate.
Plates were incubated at 8uC with gentle shaking for 20 h. FP
measurements were taken and the inhibitor concentration at
which 50% of bound Cy3b-GA was displaced (IC50) was
determined using nonlinear regression with a four parameter
logistic equation (GraphPad Prism software).
Drugs
The five new compounds selected for in vitro testing on B. pahangi
were NVP-AUY922, NVP-BEP800, SNX-2112, SNX-9203 and
BIIB021. GA was used as a positive control in some experiments.
All compounds were supplied by Selleck Chemicals (www.
selleckchem.com), with the exception of GA, which was supplied
by MBL International Corporation (Woburn, MA). Drugs were
dissolved in DMSO to give a stock solution of 10 mM, then
aliquoted and stored at 220uC. Working concentrations of drugs
were prepared on the day of use by dilution in tissue culture
medium. For in vivo studies, NVP-AUY922 was purchased from
LC Laboratories (www.LCLabs.com) and dissolved in DMSO at
50 mg/ml.
Author Summary
Adult filarial worms are long-lived nematode parasites that
have proved very difficult to kill with existing drugs.
Current campaigns for the control or elimination of these
parasites are largely based on treatment with drugs such
as diethylcarbamazine or ivermectin, that preferentially kill
the first stage larvae of the parasite, the microfilariae. As
microfilariae repopulate the body from unaffected adult
worms, repeated dosing with these drugs is required over
the long reproductive life span of the worm. The
availability of compounds with macrofilaricidal activity
would help facilitate the goal of controlling filarial
infections. Hsp90 is a recognized target in tumor cells:
consequently many oncology programs have developed
small molecule inhibitors of Hsp90, several of which are
commercially available. Here we provide proof of principle
that inhibition of Hsp90 is lethal to adult Brugia worms in
vivo, as well as in vitro, suggesting that these compounds
may have potential for further development as macro-
filaricidal drugs.
Hsp90 Inhibitors in Filarial Infection
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Effect of inhibitors on B. pahangi viability in vitro
As adult Brugia worms are limited in numbers, initial exper-
iments assessed the effect of each drug on Mf viability. Mf were
purified from infected animals essentially as described previously
[26]. In brief, following lavage of the peritoneal cavity of an
infected animal with Hanks Balanced Salt Solution (HBSS) pre-
warmed to 37uC, Mf were collected by centrifugation and then
purified from host cells by centrifugation through lymphoprep
(Sigma). This procedure was repeated twice. Mf were collected
from the pellet, washed twice in HBSS and once in worm culture
medium (WCM) which comprised RPMI 1640, (Invitrogen Cat
No: 52400), containing 5% heat inactivated fetal calf serum, 1%
glucose, 100 units/ml penicillin and 100 mg/ml streptomycin (all
Invitrogen). Mf were then dispensed into the wells of a 24-well
plate to give approximately 200 Mf in 2.0 ml, using a single well
for each drug concentration. All procedures were carried out using
aseptic techniques. The five novel compounds, plus GA and
medium alone controls, were tested three times against Mf over
the full range of concentrations.
For adult worm assays, adult female B. pahangi, 3–4 months old,
were incubated individually in 2.0 ml of WCM overnight in 24-
well plates and pre-screened for Mf production. Any worms that
failed to produce Mf overnight were discarded. For the drug
experiments, six female worms of B. pahangi for each concentration
of drug were cultured individually in 24-well plates in 2.0 ml of
WCM containing drug, or carrier alone (DMSO) at a concentra-
tion equal to that in the highest concentration of drug. In some
experiments, GA was used as a positive control. Initially, all five
compounds were tested over selected concentrations starting at
2 mM to 100 nM (see Results for details). For Hsp90 inhibitors, Mf
output by individual female worms is a sensitive indicator of adult
worm viability and, in most experiments, was assessed at 72 h. In
addition, adult worms were examined microscopically on a daily
basis for 7–10 days to determine whether lower concentrations of
drugs had any effects over a longer period of incubation. Results
are expressed as mean Mf output 6 SD over a 72 h period.
Statistical significance between groups was calculated using the
MannWhitney test with P values,0.05 being considered significant.
In two additional experiments, adult worms were exposed to a
short 24 h incubation in 250, 25 or 10 nM NVP-AUY922 or
DMSO in medium alone, using six worms per concentration as
described above. After 24 h in drug, adult worms were removed,
washed out of drug and incubated in medium alone. Mf output
was counted after 24 h in drug and again after 24 h or 48 h in
medium alone. Plates were maintained for up to 10 days and the
condition of adult parasites noted at regular intervals. In one
experiment the effect of GA on Mf output by adult B. malayi
worms was compared with B. pahangi. B. malayi worms were kindly
provided by Prof. R. Maizels (University of Edinburgh). In this
experiment, Mf were counted after 48 h of culture in GA at
2.0 mM and 1.0 mM GA. In all in vitro experiments, plates were
viewed daily and the motility and condition of the parasites noted
by two independent observers, of whom one was unaware of the
contents of the well.
L3 stages were harvested from mosquitoes nine days post-
infection. L3 were picked individually with a fine glass pipette,
counted and washed three times in HBSS containing 1000 units/
ml of penicillin and 1000 mg/ml streptomycin by sedimentation at
room temperature. 20–30 L3 per well were plated out in duplicate
in 24-well plates in 2.0 ml of WCM containing drug, or carrier
alone (DMSO) and cultured at 37uC for up to 7 days. NVP-
AUY922 was tested at a range of concentrations: 500, 250, 100,
50, 25, 10, 5.0, 1.0, 0.5 and 0.1 nM. This experiment was
repeated twice.
In vivo testing of NVP-AUY922
Adult worms were removed from the peritoneal cavity of
infected jirds and rinsed in HBSS. 10 adult female worms were
transplanted into the peritoneal cavity of each of ten male BALB/c
mouse using standard methods [27,28]. Adult worms were
transferred into the peritoneal cavity of anaesthetized mice using
a blunted glass hook. Not all mice received the full quota of 10
worms (see Table 1). The stock solution of drug was diluted to
5 mg/ml in sterile PBS containing Tween 20, to a final
concentration 5%, and DMSO to a final concentration of 10%,
as detailed previously [29]. Five mice were treated with 50 mg/Kg
NVP-AUY922 and five with sterile PBS/Tween 20/DMSO by
intra-peritoneal injection at three time points: day 0 (7 days post-
transplantation), day 3 and day 7. This dose was selected on the
basis of previous studies in a mouse xenograft model [29]. Adult
worms and Mf were recovered 9 days after the last dose of drug by
peritoneal lavage with pre-warmed HBSS. The condition of any
adult worms recovered was noted. Mf in the first 12 ml of
peritoneal washings were pelleted by centrifugation and fixed in
2% formalin in water and stored at 4uC until counted. Mice were
weighed at each time point to monitor any possible weight loss.
Results
A fluorescence polarization (FP) assay shows binding of
various classes of Hsp90 inhibitor to both B. malayi and B.
pahangi and to human Hsp90a
Several classes of inhibitor were screened against B. pahangi or B.
malayi lysates, as well as human Hsp90a, using the FP assay
originally developed as a high throughput screen for Hsp90
inhibitors in tumor cells, as previously applied to Brugia [12]. This
assay is based on the ability of small molecules to inhibit the
binding of Cy3B labeled GA to Hsp90. Table 2 shows the range of
IC50 values for the binding of selected compounds to B. pahangi, B.
malayi or human Hsp90a. In general, most compounds bound to
parasite-derived and human Hsp90 with broadly similar affinities.
Several compounds bound worm Hsp90 with high affinity,
including NVP-AUY922 and VER-50589, each of which bound
Brugia Hsp90 at low nanomolar concentrations (IC50 1–2 nM). A
second group of compounds including GA, PU-H71, SNX-2112,
SNX-9203, BIIB021 and VER-49009 bound BrugiaHsp90 with an
IC50 in the range of 10–20 nM. Most drugs bound to Hsp90 from
both species of Brugia with broadly similar affinity; CAY10607 was
Table 1. Recovery of adult worms and Mf from mice post-
NVP-AUY922 treatment.
Group Treated Control
No. mice with worms 5/5 5/5
No. mice with viable worms 2/5 5/5
Total number worms recovered 8/48** 26/47**
No. viable worms recovered (mean % 6 SD) 2 (4.466.0) 24 (51.6618.5)
No. mice with live Mf 2/5 5/5
Mean no Mf per mouse 473065101 45,880617687
**not every animal received the full complement of 10 female worms.
Recoveries from individual drug-treated mice: 3/10; 1/10; 2/9; 1/9; 1/10.
Only 2 of the 8 worms recovered were normal, all others were coated in cells
and largely immobile
Recoveries from individual control animals: 8/9; 3/10; 4/10; 6/10; 5/10. All worms
recovered from control animals showed normal motility and had no adherent
cells with the exception of a single worm, in each of two mice.
doi:10.1371/journal.pntd.0002699.t001
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an exception in this respect, showing a 10-fold higher affinity for B.
pahangi Hsp90 compared to B. malayi Hsp90.
Pre-screening using Mf identifies a spectrum of drug
activity
We initially compared the efficacy of Hsp90 inhibitors against
Mf as this life cycle stage is extremely abundant, while the
numbers of adult worms are more restricted. In these experiments
six drugs, representing five different chemotypes were selected
including NVP-AUY922, NVP-BEP800, SNX-2112, SNX-9203,
BIIB021 and GA (see Fig. 1 for drug structures), were tested over
ten doubling dilutions from 4.0 mM to 0.976 nM and compared
with the DMSO vehicle. The results of these experiments were
clear-cut: NVP-AUY922 was by far the most effective compound
tested, killing 100% of Mf by day 7 at all concentrations down to
and including 1.95 nM. At the lowest concentration of NVP-
AUY922 tested (0.976 nM), ,75% of the Mf were dead after 7
days incubation. In contrast, a concentration of 500 nM NVP-
BEP800 was required to kill the majority of Mf by day 7, with
,50% death at 250 nM. Lower concentrations of NVP-BEP800
affected Mf motility but did not kill substantial numbers of worms.
For the SNX compounds, SNX-2112 killed approximately 50% of
Mf at 500 nM by day 7, while at 250 nM, Mf were very sluggish
but still alive. SNX-9203 was slightly more effective at lower
concentrations, killing ,90% of Mf at 500 nM after 7 days
exposure, while at 250 nM most worms were alive but were much
less motile than controls. Finally, BIIB021 was active only at
4.0 mM, while lower concentrations affected worm motility but did
not kill the worms within a 7-day period. In comparison, GA killed
,90% of the Mf at 31.25 nM, while at 15.6 nM ,50% of the Mf
died, similar to the effective dose reported previously [11]. Thus,
NVP-AUY922 was the most efficient inhibitor of Hsp90 as judged
by Mf killing followed by GA, while BIIB021 was the least effective
and the SNX compounds and NVP-BEP800 had broadly similar
effects on Mf viability (see Table 3 for summary).
NVP-AUY922 affects Mf output by adult worms at low
nanomolar concentrations
We have previously described a sensitive assay to record the
effect of GA and the purine scaffold inhibitors on adult worm
viability that involves counting Mf output over a designated time
of exposure to inhibitor [11,12]. In initial experiments, all five new
compounds were screened against adult female worms at
concentrations ranging from 2.0 mM to 100 nM and Mf output
and adult worm viability monitored over a 7-day period (data not
shown). Three of the five compounds tested (NVP-AUY922, NVP-
BEP800 and SNX-9203) had a significant effect on Mf output at
all doses tested including 100 nM, while SNX-2112 was significant
only at 500 nM and BIIB021 at 2.0 mM. In additional experi-
ments, NVP-BEP800 and the SNX compounds were further
titrated from 500 nM to 1.0 nM to estimate the minimal effective
concentration. For all three drugs a concentration of 500 nM was
required to consistently show a significant effect on Mf output by
adult worms in replicate experiments.
Further experiments dealt only with the most effective compound
NVP-AUY922, which was titrated over a range of concentrations
from 500 nM to 1.0 nM. Following 72 h of exposure to all
concentrations from 500 nM to 10 nMNVP-AUY922, a significant
inhibitory effect on Mf output was observed (P= 0.0087 for 10 nM
vs DMSO, see Fig. 2). Continuing the cultures for a further three
days in the presence of drug resulted in a significant decrease in Mf
output at 5.0 nM (P=0.0043) but not at 1.0 nM. By 6 days of
exposure all adult worms were dead at concentrations of 100 nM
NVP-AUY922 and above, and, in a typical experiment (shown in
Fig. 2), 4/6 worms were dead at 50 nM drug and 3/6 were dead at
25 nM drug. The remaining worms although alive, were extremely
sluggish. Although the motility of the adult worms was affected by
exposure to lower concentrations of NVP-AUY922 (10 and
5.0 nM), they did not die at these concentrations. Worms that
were dying tended to burst and release their uterine contents and
wells contained many embryonic stages in addition to Mf.
Confirmation that NVP-AUY922 has a direct macrofilaricidal
effect was obtained by exposing male worms to a range of
concentrations from 5.0 mM to 100 nM. By day 7 of exposure
100% of male worms exposed to 100 nM drug were dead.
NVP-AUY922 affects the L3 stage of B. pahangi
While for human filarial parasites, drugs that target adult worms
are the priority, it was of interest to determine whether NVP-
AUY922 also killed the infective form of the parasite, the L3. In
these experiments, L3 were harvested directly from mosquitoes,
washed and exposed to varying concentrations of NVP-AUY922
from 500 nM to 0.1 nM in WCM. After 6 days exposure to drug,
100% of L3 were dead at all concentration down to and including
10 nM. At 5.0 nM approximately 30% of parasites were dead and
the remainder were moving very slowly. At this time point there
was no significant mortality in control wells and, at concentrations
of 1 nM or below, no effect on the L3 was observed. Thus NVP-
AUY922 is toxic to L3 stages at relatively low concentrations.
NVP-AUY922 is effective against adult worms following a
short-term exposure in vitro
In the experiments described above, adult worms or Mf were
continuously exposed to drug and viability assessed. However, as
any drug that might be used against filarial worms in vivo would be
required to exert its effect over a limited period of time, we carried
out two additional experiments to determine the outcome of
exposing adult female worms to NVP-AUY922 for a 24 h period
only. In these experiments six adult female worms per group were
Table 2. Binding affinity of various Hsp90 inhibitors versus
human Hsp90a, B. pahangi and B. malayi Hsp90 in the FP
assay.
Compound
HsHsp90a IC50
(nM)a
B. pahangi IC50
(nM)a
B. malayi IC50
(nM)a
Geldanamycin 8.7 (7.1–11) 6.4 (5.3–7.8) 12 (9.5–15)
17-AAG 12 (8.6–18) 8.0 (7.1–9.0) 2.5 (2.0–3.3)
CCT018159 270 (190–400) 240 (180–320) 330 (280–390)
VER-49009 8.0 (5.8–11) 11 (8.1–15) 14 (11–17)
VER-50589 1.5 (1.3–1.8) 0.54 (0.40–0.72) 1.2 (0.99–1.4)
NVP-AUY922 1.1 (1.0–1.4)) 0.64 (0.42–1.0) 0.95 (0.68–1.3)
CAY10607 2.2 (1.7–2.8) 1.6 (1.3–2.0) 16 (12–22)
NVP-BEP800 13 (8.7–18) 6.9 (3.7–13) 8.7 (6.2–12)
BIIB021 2.6 (1.7–4.2) 16 (14–18) 14 (12–17)
PU-H71 10 (6.6–15) 17 (14–21) 27 (22–34)
SNX-2112 4.6 (3.5–6.0) 15 (6.7–35) 20 (13–33)
SNX-9203 3.8 (2.8–5.0) 10 (5.3–19) 11 (7.1–18)
HSP990 1.4 (1.1–1.8) nd 2.3 (1.6–3.3)
aBest fit (95% confidence intervals).
nd =not determined.
doi:10.1371/journal.pntd.0002699.t002
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cultured individually with 250, 25 or 10 nM NVP-AUY922 or the
appropriate concentration of DMSO alone for 24 h. Worms were
then washed free of drug and cultured in medium alone for a
further 7–9 days. After 24 h in drug, significantly fewer Mf were
produced at 250 nM and at 25 nM NVP-AUY922 (P= 0.0043 for
both concentrations) but no significant difference was observed in
Mf output in worms incubated with 10 nM drug. After 24 h in
drug and 24 h in medium alone, Mf production was almost
completely inhibited from worms cultured in 250 nM drug (mean
of 11623 Mf) or 25 nM drug (mean of 100660 Mf) compared to
DMSO controls (16586198, P,0.05 for both 250 nm and 25 nM
drug). Although worms exposed to 10 nM drug for 24 h produced
fewer Mf (mean 9106674 Mf) than DMSO controls this difference
failed to reach significance (P= 0.0635). However following 24 h
in drug and 48 h in medium alone, adult worms exposed to
10 nM NVP-AUY922 for 24 h produced significantly fewer Mf
than control worms (P = 0.0317) (see Fig. 3). Adult worms were
clearly affected by a short-term exposure to 250 nM NVP-
AUY922, being much less motile than control worms after 24 h in
medium alone. By 48 h they were elongate and by 9 days in
medium alone, they were barely moving, but they were still alive.
Worms exposed to 25 nM NVP-AUY922 were also noticeably
more sluggish than control worms at day 9, while no obvious
difference was observed between those incubated in 10 nM drug
and DMSO controls. The experiment was discontinued at this
point.
B. malayi and B. pahangi adult females are equally
sensitive to inhibition of Hsp90
Most of our experiments have been carried out using B. pahangi,
a close relative of the human parasite, B. malayi. We compared the
efficacy of GA at two concentrations (1.0 and 2.0 mM) on B. malayi
in parallel experiments with B. pahangi. Not surprisingly, given the
degree of amino acid identity between Hsp90 in the two species
(93.5% identical), both were equally sensitive to Hsp90 inhibition.
In this experiment, the reduction in Mf output at any one
concentration of drug was almost identical: at 2.0 mM GA, there
was a 93% reduction in Mf output in B. malayi and 92% with B.
pahangi while at 1.0 mM, there was a 74% reduction in Mf output
with B. malayi and a 78% reduction with B. pahangi after 48 h of
drug exposure (P= 0.0043 for all concentrations of GA versus
DMSO control).
Testing NVP-AUY922 in vivo
As NVP-AUY922 appeared to be extremely active at low
concentrations after a short exposure in vitro, it was pertinent to
determine whether it would have activity in vivo against adult
worms transplanted into the peritoneal cavity of BALB/c mice.
Three animals in the treated group were given 10 adult worms,
while the remaining two mice received 9 worms, while in the
control group, one animal received 9 worms, one received 8
worms and the remaining three mice received 10 worms.
Following adult worm transplant, mice were randomly assigned
to a treatment group (five per group) and received either 50 mg/
Kg NVP-AUY922 at three time points by intra-peritoneal
injection or an injection of PBS/Tween 20/DMSO. Mice were
weighed at each treatment and prior to recovery of adult worms,
but no weight loss was observed in drug-treated animals over the
time course of the experiment. Adult worms were recovered 9 days
after the last injection of drug, at which point there was a
significant reduction in worm recovery from treated mice
compared to control animals (P = 0.0109) (see Table 1). All control
animals contained live, motile adult worms with recoveries varying
from 30–78% of transplanted worms (see Table 1 for details). In
contrast, very few live worms were recovered from NVP-AUY922
treated mice (recovery of live worms ranged from 0–11%, Table 1).
Adult parasites recovered from all animals were placed in HBSS at
37uC for 2–3 hours and examined again. There was no evidence
to suggest that the adult worms recovered from drug-treated
animals regained their motility over this time period. In three out
of five treated animals, only a few dead Mf were observed in the
peritoneal washings, while the remaining two animals contained
low numbers of Mf that were very slow moving (P = 0.0079, NVP-
AUY922 versus control).
Discussion
In this paper we extend our observations on the effect of Hsp90
inhibitors on adult Brugia worms in vitro and in vivo. A panel of
commercially available Hsp90 inhibitors, all designed and
optimized for binding to human Hsp90, was profiled in FP
binding assays. The broadly similar binding affinities between
human and parasite proteins highlight the evolutionarily
Figure 1. Structures of Hsp90 inhibitors used in the in vitro
experiments. Figure shows chemical structures of Geldanamycin (GA),
NVP-AUY0922, NVP-BEP800, SNX-9203 and SNX-2112.
doi:10.1371/journal.pntd.0002699.g001
Table 3. Minimal effective doses of various compounds on
Mf viability.
Drug Concentration % death by day 7
NVP-AUY922 1.95 nM 100%
0.976 nM 75%
NVP-BEP800 250 nM 50%
SNX-9203 500 nM 90%
SNX-2112 500 nM 50%
BIIB021 4.0 mM 100%
GA 31.25 nM 90%
15.6 nM 50%
Mf were cultured in 24-well plates in 2.0 ml medium containing drug at
doubling dilutions from 4.0 mM to 0.976 nM. Plates were scored daily by
microscopy and the percentage of worms alive estimated at each time point.
Results are representative of three separate experiments.
doi:10.1371/journal.pntd.0002699.t003
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conserved structure of the nucleotide-binding domain that is
targeted by these inhibitors. Selectivity towards parasite Hsp90
would obviously be preferable, but this endeavor would require a
structure-based design effort, as recently described for trypano-
some Hsp83 (Hsp90) [30]. In the spirit of exploring the potential
for a direct repurposing strategy, the translation from parasite
Hsp90 binding to filaricidal activity was examined. Five clinically
viable compounds belonging to four different drug classes were
tested in vitro for their ability to kill Mf and inhibit Mf output from
adult female worms. The results from all three systems were
reasonably consistent and highlight the efficacy of one specific
inhibitor, NVP-AUY922. This compound showed significant
activity against adult female worms at a concentration of 25 nM
after 6 days exposure, significantly inhibiting Mf output and killing
50% of adult worms. Although lower concentrations of NVP-
AUY922 (down to 5.0 nM) showed a significant effect on Mf
Figure 2. NVP-AUY922 significantly reduces Mf output from female worms at 10 nM. Graph shows mean (6 SD) Mf output from groups of
six female B. pahangi worms after 72 h exposure to NVP-AUY922 at 500, 100, 50, 25 10, 5 and 1 nM compared to DMSO control. Mf output is
significantly different from control at all concentrations to 10 nM NVP-AUY922 (P#0.0087). Results shown are representative of three experiments. In
this experiment, cultures were continued for a further 3 days and Mf counted again. At this time point (a total of 6 days exposure to drug), Mf output
was significantly different from controls at 5 nM NVP-AUY922 (P = 0.0043) but not at 1 nM.
doi:10.1371/journal.pntd.0002699.g002
Figure 3. A 24 h exposure to NVP-AUY922 reduces Mf output from female worms. Graph shows the mean (6 SD) Mf output from groups
of six female B. pahangi worms exposed to 250 nM, 25 nM or 10 nM NVP-AUY922 for a period of 24 h only (time 0). Worms were washed free of drug
and cultures continued in medium alone for a further 24 h or 48 h and Mf output quantified. P,0.05 for 250 nM and 25 nM compared to control at
all time points; for 10 nM drug, P,0.05 for 48 h only. Results shown are representative of two experiments.
doi:10.1371/journal.pntd.0002699.g003
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output, adult worms were not killed at this concentration over the
time scale of the experiment. NVP-AUY922 showed a high affinity
for Brugia Hsp90 in the FP screen, further validating the
application of this assay as a high throughput screen. It was also
the most active compound tested in the Mf killing assay. As a
single infected animal can produce millions of Mf, these results
indicate that using Mf could provide a simple, inexpensive and
relatively high throughput pre-screen for compounds with
macrofilaricidal activity, while acknowledging that not all com-
pounds that effect Mf will also kill adult worms. The translation
from Brugia Hsp90 binding to micro- and macro-filaricidal activity
depends upon the chemotype being tested and this is evident in the
compounds used here. While NVP-AUY922 bound Brugia Hsp90
at,1 nM and had an EC50 against Mf viability in the same range,
the other compounds exhibited variable translation between the
two assays. For example, NVP-BEP800 bound quite well to Brugia
Hsp90 (,7 nM IC50) but required much higher concentrations to
kill microfilaria (,250 nM EC50) during an extended 7-day
incubation. There are many possible explanations for this
discrepancy, including failure of the compound to fully equilibrate
within the microfilariae during the experiment. It is possible that
this particular compound does not penetrate well or is actively
exported from the parasites. As more detailed studies would be
required to address this issue, we continued to focus on
compounds with the best activity against live parasites.
We assessed the effect of these inhibitors on adult female worms
by quantifying Mf output, as a measure of worm viability. Mf
output is an active process in filarial worms and relies on the
presence of live Mf in utero and on the activity of the vulva, a
muscular opening close to the anterior end of the worm. When
Hsp90 is inhibited, cessation of Mf output is a sensitive surrogate
measure of adult female worm health and appears to be one of the
first signs that worm viability is compromised. Once Mf
production ceases following exposure to Hsp90 inhibitors, it does
not resume, at least over the time scale of our in vitro experiments.
In addition, previous studies [11] demonstrated that embryogen-
esis in adult B. pahangi was disrupted upon inhibition of Hsp90 with
GA. When RNAi was used to knockdown hsp90 (daf-21) in the
free-living nematode Caenorhabditis elegans, one of the most
penetrant phenotypes observed was a protruding vulva and
sterility in the F1 generation [31]. In C. elegans, the vulva is a
complex structure, the development of which is dependent upon a
number of signaling pathways (reviewed in [32]). The vulva is
innervated by neurons and egg-laying in C. elegans (the equivalent
of Mf release in filarial worms) is regulated by multiple factors and
molecules, including neuropeptides, kinases and members of the
TGF-b signaling pathway [33].
Much less is known of the factors that regulate Mf production in
filarial nematodes, but the vulva may be particularly sensitive to
Hsp90 inhibitors, perhaps acting on various kinases required for
signaling in this structure. Alternatively, the rapid inhibition of Mf
output observed (within 24 h at high concentrations of inhibitor)
may reflect a general demise in adult female worms upon
inhibition of Hsp90. In the related filarial nematode O. volvulus,
ivermectin is reported to inhibit Mf output, while not killing the
adult worm. In cattle infected with O. ochengi, embryogenesis is
disrupted by treatment with ivermectin and an accumulation of
dead and dying Mf are observed [34], similar to that described for
female Brugia exposed to GA [11]. However, the results of the
present study show that inhibition of Hsp90 by NVP-AUY922 not
only affects Mf release but also directly affects the viability of adult
worms. This property was clearly demonstrated following in vitro
exposure of both male and female adults to the inhibitor and in vivo
administration of the inhibitor to mice following transplant of
female worms. Hsp90 functions in a complex with other proteins
to fold and/or stabilize a wide variety of client proteins, most of
which have been identified from mammalian cells or yeast. A list
of Hsp90 client proteins is curated by the Picard Lab (http://www.
picard.ch). However, we know little about the key client proteins
clients in Brugia, except by homology with known interacting
proteins identified from other systems. A better understanding of
the Hsp90 interactome in Brugia may help explain the effects
observed upon chemical inhibition of Hsp90.
As all our previous studies have focused on B. pahangi, we also
tested B. malayi in this study and showed that GA had very similar
effects upon both species. Similar data was recently published [35]
showing that GA and four derivatives of GA, were active in vitro on
adult B. malayi and the trematode parasite Schistosoma japonicum. In
that study, the lowest concentration tested was 500 nM, but
encouragingly all compounds were active against adult B. malayi at
this concentration.
Interestingly, NVP-AUY922 also showed potent activity against
the L3 stage of B. pahangi. While drugs that target the L3 stage of
filarial nematodes are not the highest priority for human use, they
are of significant interest in the veterinary field, where prophylaxis
of the dog heartworm, Dirofilaria immitis, is a major area of concern
in veterinary practice. Here, the macrocyclic lactones, such as
ivermectin and moxidectin, have been the mainstay of control for
many years. Given the recent observation on treatment failures
with ivermectin in some dogs in the Southern states of the USA
[36], there is a clear need for the development of novel compounds
to protect susceptible animals.
As a preliminary to in vivo testing, we investigated whether a
short exposure to the most effective compound identified, NVP-
AUY922, affected adult worm viability in vitro. These experiments
showed that Mf output was significantly reduced following a 24 h
exposure to all concentrations of drug including 10 nM (the lowest
concentration tested in this study), although it required an
additional 48 h incubation in medium alone to detect this effect.
However, although Mf output was significantly different between
drug exposed and control worms, a direct effect was observed at
250 nM concentration after a 24 h exposure, with adult female
worms being almost motionless after 9 days in culture. While a
24 h exposure to 25 nM NVP-AUY922 resulted in a significant
decrease in motility, the adult female worms were still alive at day
9. Whether such motility-impaired worms would be viable in vivo
in an immuno-competent host is doubtful. These data also
highlight one of the characteristics of Hsp90 inhibitors: the time
taken to kill adult worms. They do not kill rapidly, which may be a
useful attribute for in vivo use, as some of the pathogenesis of
lymphatic filariasis is associated with death of the adult worms,
and the subsequent release of antigen and the Wolbachia
endosymbiont [37].
NVP-AUY922 belongs to the isoxazole resorcinol class of Hsp90
inhibitors and has shown some promise as an anti-tumor agent in a
mouse xenograft tumor model [29,38]. In the first of these studies,
pharmacokinetic analysis showed that the plasma levels of drug
reached a maximum of 52,506 nM at 0.25 h post-dosing following
a single dose of 50 mg/Kg delivered by the intra-peritoneal route.
As a 24 h exposure to 250 nM NVP-AUY922 had a significant
deleterious effect on adult female worms, we were encouraged to
test this compound in vivo, using an adoptive transplant system in
which viable adult worms are transplanted into the peritoneal cavity
of mice [27,28]. In previous experiments with NVP-AUY922
administered in a similar dosing regimen to nude mice containing
xeno-grafted tumors, weight loss was observed [38]. However our
immune-competent animals showed no loss in weight or other
obvious deleterious effects over the time scale of the experiment.
Hsp90 Inhibitors in Filarial Infection
PLOS Neglected Tropical Diseases | www.plosntds.org 7 February 2014 | Volume 8 | Issue 2 | e2699
Adult worms were recovered nine days after the last dose of
drug, as the in vitro data indicated that it might take some time for
the drug to act. Additionally, previous studies with suramin, one of
the few compounds with activity against adult filarial worms,
demonstrated that it took approximately 6 weeks to reduce adult
worm recovery in the jird model [39]. A total of eight out of 48
transplanted female worms were recovered from drug treated
animals, but of these only two were healthy with the others being
coated in cells, indicating that they were in the process of being
cleared by the immune system. In contrast, 26 female worms out
xof 47 transplanted were recovered from animal treated with vehicle
alone. Moreover, only two of the drug-treated mice contained live
Mf, and these appeared very sluggish compared to controls. Further
studies will be required to examine alternative routes of drug
administration and to explore in more detail the mechanism by
which these inhibitors exert their macrofilaricidal effect.
The clinically viable Hsp90 inhibitors tested here are targeted
and potent towards human Hsp90 and thus may have unwanted
side effects. In this respect, the therapeutic potential of any of these
inhibitors for filarial disease will depend on the pharmacodynamic
differences between host toxicities and parasite killing. There are
pharmacokinetic data in both animals and humans available for
many of the Hsp90 inhibitors. We have used this data in
combination with in vitro worm killing assays to predict the doses of
NVP-AUY922 that would be successful in killing parasites in vivo.
While efficacy in cancer treatment likely requires chronic dosing of
near maximum tolerated doses, the treatment of parasitic diseases
would ideally necessitate a short course of treatment. It is not
currently clear whether a short treatment course with current
inhibitors would be able to clear parasites, while maintaining
appropriate safety margins. Additional studies will be required to
carefully delineate the therapeutic window of short treatment
courses. As noted earlier, the development of parasite-selective
inhibitors with reduced potential for host toxicity would be of
enormous benefit and should also be pursued.
The ubiquitous nature of Hsp90 in normal as well as
transformed cells, has led some to question the potential of this
molecule as a drug target. However, for the past 20 years, the
National Cancer Institute has advocated Hsp90 as a drug target,
since GA was first shown to exhibit anti-tumor properties. There
are currently seventeen Hsp90 inhibitors in clinical trials and a
growing arsenal of novel Hsp90 inhibitors, of structurally diverse
scaffold (reviewed in [40]). Current emphasis is on combination
therapies in which Hsp90 inhibitors are combined with other anti-
tumor drugs [41]. Whether a similar approach would further
enhance the activity of these inhibitors against adult filarial
parasites remains to be determined. However, we believe that
these studies provide data to further strengthen the contention that
inhibition of Hsp90 is a valid target for the chemotherapy of
lymphatic filariasis, while acknowledging that a significant
medicinal chemistry effort would be required to optimize the
activity of these inhibitors.
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